体液细胞外囊泡膜蛋白在制备诊断青光眼疾病产品中的用途
By extracting and separating external vesicles from peripheral blood and screening Tau and GFAP proteins as biomarkers, the problem of insufficient sensitivity in the early diagnosis of glaucoma in existing technologies has been solved, realizing non-invasive and highly sensitive POAG diagnosis and improving the accuracy and feasibility of early screening.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- WENZHOU MEDICAL UNIV
- Filing Date
- 2026-02-28
- Publication Date
- 2026-07-17
AI Technical Summary
Existing technologies are insufficient for highly sensitive, non-invasive early diagnosis of glaucoma, especially for early screening and diagnosis of primary open-angle glaucoma (POAG). Conventional methods lack sensitivity and fail to reflect the condition. Limited access to primary healthcare resources and low patient compliance also restrict their widespread application.
By extracting external vesicles from peripheral blood samples of POAG and cataract patients, and using mass spectrometry sequencing and immunoprecipitation separation technology, Tau protein and GFAP protein were screened as biomarkers to develop non-invasive detection products. Based on these proteins, products for the auxiliary diagnosis of glaucoma disease were developed.
It achieves highly sensitive, non-invasive diagnosis of POAG, improves the accuracy and feasibility of early diagnosis, provides a more precise reflection of pathological changes in the central nervous system and retinal tissue, and has high diagnostic efficacy.
Smart Images
Figure CN121741201B_ABST